Skip to main content

Beta Bionics, Inc.

corporate_fare Company Profile

Beta Bionics, Inc.

BBNX·NASDAQ·Industrial Applications And Services·CIK 0001674632

We are a commercial-stage medical device company focused on designing, developing, and selling innovative solutions to improve the health and quality of life for people with diabetes who require insulin. We achieve this by using advanced adaptive closed-loop algorithms to simplify and improve their disease treatment. Our product, the iLet Bionic Pancreas (iLet), received clearance from the U.S. Food and Drug Administration (FDA) for treating Type 1 diabetes in adults and children aged six years and older. The iLet was commercially launched in May 2023 in the United States. As of December 31, 2025, our installed base has grown to 35,011 iLets. Diabetes is a serious, chronic condition characterized by high blood glucose levels due to the body's inability to produce or effectively use insulin. People with diabetes must follow a strict daily insulin regimen to avoid serious complications. Type 1 diabetes (T1D) is an autoimmune disorder, often developing in childhood, where the immune system destroys insulin-producing cells. Approximately 1.9 million people in the United States have T1D and require daily insulin. Type 2 diabetes (T2D) is a metabolic disorder, typically developing in adulthood, where the body becomes insulin resistant, requiring increased insulin production or replacement.

Beta Bionics, Inc. (NASDAQ:BBNX) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 27 items for BBNX at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Beta Bionics Projects $131M-$136M Revenue for 2026
  • Beta Bionics Discloses High Executive Compensation and Significant Potential Dilution Ahead of Annual Meeting
  • Beta Bionics Files Shelf Registration for Future Capital Raises
  • Beta Bionics Reports Strong 2025 Revenue & Customer Growth, Addresses FDA Warning Letter
  • Beta Bionics Reports Strong Q4 & Full Year 2025 Results, Guides for Continued Growth in 2026

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$100.25M
Net Income
-$73.2M
Diluted EPS
-$1.81
Op. Cash Flow
-$50.92M
Free Cash Flow
-$56.22M
Gross Profit
$55.54M
Operating Income
-$71.68M
Cash & Equivalents
$31.58M
Debt / Equity
0.00×
Net Margin
-73.0%
Shares Outstanding
44.36M sh
Source: 10-K · filed 2026-02-24 · accession 0001193125-26-067065
$13.36
52-week range · as of 2026-10-27 $8.8 – $32.71
Market cap
$726.34M
Volume
960.3K (0.8× avg)
3-mo avg 1.2M
Live data · 2026-11-21 22:54 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BBNX - Filings & News (Page 2)

BBNX
Apr 21, 2026, 4:18 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $12.03
Real-time Price: $13.36 info
Change: +$1.33 (+11%) info
Market Cap: $726.344M info
BBNX
Apr 10, 2026, 4:05 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $8.94
Real-time Price: $13.36 info
Change: +$4.42 (+49%) info
Market Cap: $726.344M info
BBNX
Feb 24, 2026, 5:03 PM EST
Filing Type: S-3ASR
Importance Score:
7
Price at Filing: $13.40
Real-time Price: $13.36 info
Change: -$0.040 (-0.30%) info
Market Cap: $726.344M info
BBNX
Feb 24, 2026, 4:20 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $13.46
Real-time Price: $13.36 info
Change: -$0.100 (-0.74%) info
Market Cap: $726.344M info
BBNX
Feb 17, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $13.97
Real-time Price: $13.36 info
Change: -$0.610 (-4%) info
Market Cap: $726.344M info
BBNX
Jan 30, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $13.83
Real-time Price: $13.36 info
Change: -$0.470 (-3%) info
Market Cap: $726.344M info
BBNX
Jan 08, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $31.99
Real-time Price: $13.36 info
Change: -$18.63 (-58%) info
Market Cap: $726.344M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets